|
The Multidisciplinary Association for Psychedelic
Studies (MAPS) is a membership-based, IRS-approved
501 (c) (3) non-profit research and educational organization. We
assist scientists to design, fund, obtain approval for and report on
studies into the risks and benefits of MDMA,
psychedelic drugs and marijuana.
MAPS' mission is to sponsor scientific research designed to develop
psychedelics and marijuana into FDA-approved prescription medicines,
and to educate the public honestly about the risks and benefits of
these drugs. Read our strategy statement
for more information.
We need your support
so together we can make a difference. In addition to general membership
donations, MAPS is seeking to raise funds for specific research projects.
These are our funding priorities and here
are our financial reports.
For background reading, see MAPS President Rick Doblin's doctoral dissertation (Harvard, Kennedy School of Govt., 2001) "Regulation of the Medical Use of Psychedelics and Marijuana," visit our media and audio/visual archives, or peruse the latest issue of the MAPS Bulletin and our monthly news update.
|
|
 | 11/13/08 | MAPS-sponsored researcher Michael Mithoefer MD will present a poster about our flagship MDMA-assisted psychotherapy for the treatment of posttraumatic stress disorder (PTSD) to the International Society for Traumatic Stress Studies (ISTSS). ISTSS is the largest organization in the world for researchers and therapists working with PTSD patients. The 24th annual conference will take place in Chicago from November 13th through 15th. |
| 11/13/08 | We have released a news advisory to announce Dr. Michael Mithoefer s poster presentation about our MDMA/PTSD research at the International Society for Traumatic Stress Studies, (www.istss.org) 24th Annual Meeting. |
| 11/10/08 | The November email news update has been sent to MAPS' email list.
|
| 11/7/08 | The Canadian Institutional Review Board (IRB) granted conditional approval for our MDMA/PTSD protocol. |
| 11/6/08 | Chemic Labs submitted a response to a June 16, 2008, critique of our vaporizer protocol (PDF) by the National Institute on Drug Abuse (NIDA) and the Public Health Service (PHS). We submitted the protocol to NIDA/PHS on January 16, 2008, along with three letters of support from peer reviewers. More information is available on our marijuana research page |
| 11/6/08 | Chemic Labs submitted to NIDA a revised Volcano Vaporizer study protocol. |
| 10/21/08 | MAPS’ Board of Directors met in San Jose, California. The board reviewed our financial record from fiscal year 2007-08, as well as our accomplishments and upcoming goals. Our in-house accountant Josh Sonstroem attended the meeting to present our financial records and budgets. At the conclusion of the meeting, Board Members John Gilmore and Ashawna Hailey each committed $150,000 for the upcoming fiscal year 2008-09. |
|
MAPS is pleased to present the original work of two amazing Visionary Artists: Roberto Venosa and Dean Chamberlain. We are now proudly offering four special signed and numbered limited-edition prints from Dean Chamberlain's Psychedelic Pioneers series (at left), as well as limited-edition prints of Robert Venosa's portrait of Albert Hofmann, signed by Albert Hofmann himself (at right). Proceeds from the sale of these portraits will be equally divided between MAPS-sponsored psychedelic research and the respective artists.
Both Dean Chamberlain's portraits of Albert Hofmann, Laura Huxley, Ann & Sasha Shulgin and Ram Dass as well as Roberto Venosa's portrait of Albert Hofmann are all available for purchase in the MAPS Online Store. These portraits are not only a good investment and would look great on your wall, but they are also a major fundraising tool for MAPS' research projects!
|
